Sartorius (XTRA:SRT3) Stock Faces Lofty 77.8x P/E As Margin Rebound Fuels Debate

Sartorius (XTRA:SRT3) has just posted its Q2 2026 scorecard, with revenue of €911.8 million and net income of €65.9 million setting the tone for how investors will read the latest margin story. Over recent quarters the company has seen revenue move from €884.3 million in Q2 2025 through €899.1 million in Q1 2026 to €911.8 million in Q2 2026, while net income has ranged from €32.5 million to €65.9 million over the same span. This gives a clearer picture of how the top and bottom lines are tracking into the current release. With trailing 12 month earnings up 88.4% and the net profit margin at 5.5%, the focus now is firmly on how durable these margins look relative to the growth that analysts expect ahead.

See our full analysis for Sartorius.

With the headline numbers in place, the next step is to weigh them against the prevailing Sartorius narratives to see which storylines the latest results support and which ones they start to challenge.

Curious how numbers become stories that shape markets? Explore Community Narratives

88.4% earnings growth meets 5.5% margin

• Over the last 12 months, Sartorius generated €3.6b in revenue and €196.1 million in net income, which works out to an earnings growth rate of 88.4% and a 5.5% net profit margin compared with 3% a year earlier.
• What stands out for a bullish view is that this strong 12 month earnings result contrasts with a five year history where earnings declined about 29.1% per year, so investors are weighing whether the recent 88.4% growth and higher 5.5% margin signal a shift or just a better year.
  • Supporters of the optimistic angle point to the step up from a 3% to 5.5% net margin alongside the €3.6b revenue base as evidence that profitability on current sales is healthier than it was a year ago.
  • At the same time, the five year decline rate reminds you that longer term earnings have not followed a straight upward path, so the latest figures sit against a backdrop of earlier profit pressure rather than an uninterrupted growth story.

Curious how others are joining the dots between Sartorius's 88.4% earnings growth and its mixed five year record, and what long term stories they are building from these numbers, Curious how numbers become stories that shape markets? Explore Community Narratives.

P/E of 77.8x and DCF fair value gap

• Sartorius trades on a trailing P/E of 77.8x compared with 36.6x for the Global Life Sciences industry and 31.3x for peers, while the DCF fair value in the data is €301.42 against a share price of €221.10, implying the stock sits about 26.6% below that DCF figure.
• What challenges a straightforward bearish valuation take is that the high 77.8x P/E multiple sits alongside a modelled DCF fair value that is above the current €221.10 price, so investors who focus on earnings multiples and those who focus on DCF could reach different views using the same €3.6b revenue and €196.1 million earnings base.
  • Critics who focus on the bearish angle will highlight that paying 77.8x trailing earnings is rich versus the 36.6x industry average and 31.3x peer average, especially given the five year period where earnings declined 29.1% per year.
  • On the other hand, investors who rely on the DCF fair value of €301.42 may view the 26.6% gap from the €221.10 share price, combined with the 5.5% trailing margin and 88.4% earnings growth, as pointing to potential valuation upside if the inputs behind that DCF hold.

9% revenue outlook with 20.3% earnings growth forecast

• The data shows analysts forecasting about 9% annual revenue growth alongside roughly 20.3% annual earnings growth over the next three years, compared with the trailing 12 month revenue of €3.6b and earnings of €196.1 million that produced the recent 5.5% net margin.
• What heavily supports the bullish case is that these projected growth rates build on a starting point where earnings already grew 88.4% over the last year and margins rose from 3% to 5.5%, yet the five year record of earnings declining 29.1% per year adds a cautionary note that readers should factor in.
  • Supporters of a growth focused view can point out that, if earnings were to grow in line with the 20.3% forecasts on top of the current €196.1 million base, the company would be expanding profit from a much higher level than a year ago rather than from a low starting point.
  • Against that, the earlier multi year earnings decline shows that past performance has not always matched optimistic forecasts, so some investors may want to see how the 9% revenue and 20.3% earnings growth projections track against actual reported numbers in coming periods before placing too much weight on them.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Sartorius's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the mixed tone around Sartorius leaves you undecided, take a closer look at the numbers, time frames and assumptions that matter most to you, then weigh the 4 key rewards and 1 important warning sign.

See What Else Is Out There

Despite Sartorius reporting 88.4% earnings growth and a 5.5% margin, the high 77.8x P/E and history of multi year earnings decline keep valuation and consistency in question.

If Sartorius's rich earnings multiple and uneven track record make you hesitate, use the 236 high quality undervalued stocks to quickly zero in on companies where pricing looks more grounded in recent performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com